Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GCL vs NIVF: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GCL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

GCL Overall Winner 6-Pillar Tally: GCL 3 – 2 NIVF (1 Tie) Matrix Metrics: GCL 5 – 3 NIVF

As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over NewGenIvf Group Limited Class A (NIVF) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas NIVF carries 45.8/100 (HOLD) at $0.20 (N/M Forward P/E, -238.2% operating margin).

  • Composite vs. Pillar Nuance: While NIVF currently prints a higher short-term Unified Composite Score (45.8/100 HOLD vs. GCL 31.6/100 SELL), GCL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. -238.2% operating margin) and revenue trajectory (+53.8% vs. -4.7% YoY).
  • Technical & Structure Timing Caution: GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GCL vs NIVF
GCL NASDAQ Head-to-Head Winner
GCL Global Holdings Ltd Ordinary Shares
Services-Prepackaged Software
$1.16
-2.93% 1D
Market Cap $153.0M
TTM Revenue $239M
Forward P/E N/M
Beta / 30D Vol 1.52β · 75% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 50.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (22.9% over 20 days), RSI 71
RSI-14: 70.6 · SMA20: $0.98 · SMA50: $0.82
NIVF NASDAQ
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.20
-11.33% 1D
Market Cap $369,508
TTM Revenue $4.6M
Forward P/E N/M
Beta / 30D Vol 0.07β · 3093% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 50.0 Fund 44.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.1%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $0.64 · SMA50: $0.54

6-Pillar Scorecard Institutional Category Breakdown (GCL 3 – 2 NIVF)

Columns: Metric · GCL · NIVF
1. Valuation Multiples NIVF
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x 0.1x
2. Growth & Scale GCL
Revenue Growth (YoY) +53.8% -4.7%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $239M $4.6M
Market Cap $153.0M $369,508
3. Profitability & Quality NIVF
Gross Margin 10.3% 23.9%
Operating Margin -5.5% -238.2%
Net Profit Margin -10.5% 24.2%
Return on Equity (ROE) -67.3% 5.5%
4. Balance Sheet & Cash Flow GCL
Cash Generation (TTM) -$12M EBITDA -$11M EBITDA
Cash Flow Margin -4.9% EBITDA Mgn N/A
Net Cash / Leverage $0.29 Book/Sh · -67.3% ROE $733.75 Book/Sh · 5.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat GCL
OpEx & R&D Intensity 15.8% of Rev ($38M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Electronic Gaming & Multimedia Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GCL (5) vs NIVF (3)
Institutional Metric GCL NIVF Criterion Row Edge
Market Capitalization
Scale
$153.0M $369,508 Larger Scale GCL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+53.8% -4.7% Higher Growth GCL
Operating Margin (TTM)
Profitability
-5.5% -238.2% Higher Margin GCL
Net Profit Margin
Profitability
-10.5% 24.2% Higher Margin NIVF
Return on Equity (ROE)
Capital Efficiency
-67.3% 5.5% Higher ROE NIVF
52-Week Range Position
Momentum
57% ($0–$2) 5% ($0–$3) Stronger Trend GCL
Beta / 30D Volatility
Risk Regime
1.52β · 75% Vol 0.07β · 3093% Vol Lower Realized Risk GCL
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 45.8 / 100 (HOLD) Higher Composite NIVF
Trailing 12M Revenue (USD)
Operating Scale
$239M $4.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
10.3% 23.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($0.29 Book/Sh · -67.3% ROE) -$11M EBITDA ($733.75 Book/Sh · 5.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GCL +59.68 pp
GCL: +33.16% · NIVF: -26.52%
3M Horizon GCL +164.11 pp
GCL: +101.42% · NIVF: -62.69%
6M Horizon GCL +240.92 pp
GCL: +163.7% · NIVF: -77.22%
1Y Horizon GCL +16.43 pp
GCL: -28.4% · NIVF: -44.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GCL vs NIVF. Trailing 12-month operating profitability (GCL -5.5% vs NIVF -238.2%) and valuation multiples (GCL N/M vs NIVF N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$239M
Gross Margin10.3%
Op. Margin-5.5%
ROE / Fwd P/E-67.3% · N/M
NIVF ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.6M
Gross Margin23.9%
Op. Margin-238.2%
ROE / Fwd P/E5.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NIVF UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NIVF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GCL Moat Profile Cyclical / Execution-Driven Positioning
Electronic Gaming & Multimedia Operator
Competes within the Electronic Gaming & Multimedia value chain with $153.0M market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment 15.8% of Rev ($38M)
90D Engineering Disclosures 0 Published
NIVF Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $369,508 market capitalization and -238.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GCL vs NIVF Key Questions & Quantitative Answers

As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over NewGenIvf Group Limited Class A (NIVF) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas NIVF carries 45.8/100 (HOLD) at $0.20 (N/M Forward P/E, -238.2% operating margin). Composite vs. Pillar Nuance: While NIVF currently prints a higher short-term Unified Composite Score (45.8/100 HOLD vs. GCL 31.6/100 SELL), GCL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. -238.2% operating margin) and revenue trajectory (+53.8% vs. -4.7% YoY). Technical & Structure Timing Caution: GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GCL leads the Growth & Scale pillar: GCL posts +53.8% YoY revenue growth and N/A YoY earnings growth on $239M TTM revenue (10.3% gross margin, -5.5% operating margin), compared with NIVF at -4.7% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (23.9% gross margin, -238.2% operating margin). On trailing 12-month operating scale, GCL generates $239M in USD-normalized revenue versus $4.6M for NIVF. In operating R&D and SG&A reinvestment, GCL deploys 15.8% of Rev ($38M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NIVF.

NIVF screens cheaper on headline valuation multiples. GCL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-4.9% EBITDA margin), whereas NIVF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GCL (-67.3% ROE) versus NIVF (5.5% ROE) capital efficiency.

In options market volatility and institutional positioning, GCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 75% Vol realized risk). By comparison, NIVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.07β · 3093% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.